Prostate cancer is a deadly condition, even though new effective treatments are emerging. It is actually the second most common cancer in men worldwide and the incidence rate of this disease is around 1.1-1.5 per 1000 men every year. Now scientists at UCL found that a new prostate cancer drug abiraterone could halve risk of prostate cancer death...
Tag: <span>abiraterone</span>
Post
Abiraterone could halve risk of prostate cancer death for some patients
by Institute of Cancer Research Credit: CC0 Public Domain Adding abiraterone to the standard treatment for locally advanced prostate cancer, where the cancer has a high chance of spreading, could halve the risk of death from the disease. The researchers suggest that hormone therapy using abiraterone with prednisolone, could significantly reduce prostate cancer deaths and improve outcomes...
Post
Researchers Optimistic After Dose-Determining Trial of Compound Against Metastatic Castration-Resistant Prostate Cancer
This news or article is intended for readers with certain scientific or professional knowledge in the field. A new multi-institution, dose-determining clinical trial of a compound against metastatic, castration-resistant prostate cancer showed promising results, researchers reported in Clinical Cancer Research. The phase 1b/2a study of the pan-BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide was...
Post
Breakthrough discovery to transform prostate cancer treatment
A NOVEL FORMULATION OF THE PROSTATE CANCER DRUG ABIRATERONE ACETATE – CURRENTLY MARKETED AS ZYTIGA – WILL DRAMATICALLY IMPROVE THE QUALITY OF LIFE FOR PEOPLE SUFFERING FROM PROSTATE CANCER.view more CREDIT: HAYLEY SCHULTZ/UNISA A novel formulation of the prostate cancer drug abiraterone acetate – currently marketed as Zytiga – will dramatically improve the quality of...
Post
Adding abiraterone to standard treatment improves prostate cancer survival by 40 percent
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one of the largest ever clinical trials for prostate cancer presented at the 2017 ASCO Annual Meeting in Chicago and published in the New England Journal of Medicine today (Saturday). The results...